[Meta] proposal — a flair for gastric emptying posts
Proposal, not a decision: proposal — a flair for gastric emptying posts.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.
The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Why mechanism talk keeps misleading people, including me.
A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.
The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.
Asked for a citation rather than removing. On this board a claim without one is an invitation, not an offence.
albumin binding is most of the half-life story
Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.
This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.
receptor distribution is why the side effects are where they are
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.
[removed by moderator]
Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.
Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.
gastric emptying slows, it does not stop
preclinical is not clinical and rodents are not small people
GIP is the arm people argue about because the biology is genuinely unsettled
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
- 1Receptor expression in a tissue is necessary but not sufficient for an…6 comments in this branch · started by u/maintenance_mode_max